publication date: Dec. 19, 2010

In this issue: 

An “insurgency” targets randomized trials, demands access to investigational drugs.

In this 16-page issue: The Wall Street Journal editorial page leads campaign against efficacy standard.

Critics of FDA misunderstand Bayesian analysis, statisticians say.

Abigail Alliance says statisticians usurped control of oncology. Milken’s optimism fuels the movement.

Gottlieb questions ODAC’s independence.

Download (PDF 451KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.